Stock Events

PureTech Health 

GBX169.2
18
-GBX2.8-1.63% Today

Statistics

Day High
175
Day Low
168.8
52W High
238.5
52W Low
139
Volume
484,197
Avg. Volume
407,009
Mkt Cap
430.77M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27AugConfirmed
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Next
-4.09
-2.73
-1.36
0
Expected EPS
-0.303
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRTC.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.12B
Vertex Pharmaceuticals is a biotech company focusing on creating transformative medicines for serious diseases, similar to PureTech's approach in healthcare innovation.
Regeneron Pharmaceuticals
REGN
Mkt Cap118.74B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of medicines for serious medical conditions, competing in the biopharmaceutical space with PureTech.
Gilead Sciences
GILD
Mkt Cap87.16B
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, overlapping with PureTech's mission.
AMGEN
AMGN
Mkt Cap177.47B
Amgen is a global biotechnology company that develops and produces therapeutics in areas such as oncology and cardiovascular disease, competing with PureTech in the biotech innovation sector.
Biogen
BIIB
Mkt Cap33.5B
Biogen is a biotechnology company specializing in therapies for neurological diseases, directly competing with PureTech Health in the biotech and pharmaceutical innovation space.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie is a pharmaceutical company that researches and develops a broad range of therapeutic products, potentially competing with PureTech in various healthcare areas.
Moderna
MRNA
Mkt Cap46.55B
Moderna is a leader in mRNA technology, developing transformative medicines for a wide range of diseases and conditions, including areas where PureTech is active.
Bristol-Myers Squibb
BMY
Mkt Cap82.02B
Bristol Myers Squibb is a global biopharmaceutical company whose mission overlaps with PureTech's in discovering, developing, and delivering innovative medicines.
Novartis
NVS
Mkt Cap244.62B
Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide, competing with PureTech in the broad healthcare and pharmaceutical sectors.
Pfizer
PFE
Mkt Cap163.88B
Pfizer is a global biopharmaceutical company with a wide range of products in various therapeutic areas, making it a competitor to PureTech in the healthcare innovation field.

About

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Show more...
CEO
Ms. Daphne Zohar
Employees
90
Country
GB
ISIN
GB00BY2Z0H74
WKN
000A14VK6

Listings